Literature DB >> 30032204

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection.

E P Scully1, R L Rutishauser2, C R Simoneau3, H Delagrèverie4, Z Euler5, C Thanh2, J Z Li6, H Hartig7, S Bakkour8, M Busch8, G Alter5, F M Marty6, C-C Wang9, S G Deeks7, J Lorch10, T J Henrich11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30032204      PMCID： PMC6225895          DOI： 10.1093/annonc/mdy259

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab.

Authors:  Gwenaëlle Le Garff; Assia Samri; Sidonie Lambert-Niclot; Sophie Even; Armelle Lavolé; Jacques Cadranel; Jean-Philippe Spano; Brigitte Autran; Anne-Geneviève Marcelin; Amélie Guihot
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

2.  Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.

Authors:  A Guihot; A-G Marcelin; M-A Massiani; A Samri; C Soulié; B Autran; J-P Spano
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 32.976

Review 3.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

4.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Authors:  Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069
  4 in total
  30 in total

Review 1.  Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

Authors:  Daniel C Rogan; Mark Connors
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

Review 2.  Between a shock and a hard place: challenges and developments in HIV latency reversal.

Authors:  Jennifer M Zerbato; Harrison V Purves; Sharon R Lewin; Thomas A Rasmussen
Journal:  Curr Opin Virol       Date:  2019-04-29       Impact factor: 7.090

3.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

Review 4.  Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.

Authors:  Sydney Corey; Bryan R Smith; Irene C M Cortese
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-01       Impact factor: 5.495

5.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption.

Authors:  Justin Harper; Shari Gordon; Chi Ngai Chan; Hong Wang; Emily Lindemuth; Cristin Galardi; Shane D Falcinelli; Samuel L M Raines; Jenna L Read; Kevin Nguyen; Colleen S McGary; Michael Nekorchuk; Kathleen Busman-Sahay; James Schawalder; Colin King; Maria Pino; Luca Micci; Barbara Cervasi; Sherrie Jean; Andrew Sanderson; Brian Johns; A Alicia Koblansky; Heather Amrine-Madsen; Jeffrey Lifson; David M Margolis; Guido Silvestri; Katharine J Bar; David Favre; Jacob D Estes; Mirko Paiardini
Journal:  Nat Med       Date:  2020-03-16       Impact factor: 53.440

Review 6.  Cancer immunotherapy of patients with HIV infection.

Authors:  M Gonzalez-Cao; J Martinez-Picado; N Karachaliou; R Rosell; A Meyerhans
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405

Review 7.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

8.  The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy.

Authors:  Jillian S Y Lau; James H McMahon; Celine Gubser; Ajantha Solomon; Chris Y H Chiu; Ashanti Dantanarayana; Socheata Chea; Surekha Tennakoon; Jennifer M Zerbato; Jill Garlick; Vincent Morcilla; Sarah Palmer; Sharon R Lewin; Thomas A Rasmussen
Journal:  AIDS       Date:  2021-08-01       Impact factor: 4.632

Review 9.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

10.  Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.

Authors:  Thomas A Rasmussen; Lakshmi Rajdev; Ajantha Rhodes; Ashanti Dantanarayana; Surekha Tennakoon; Socheata Chea; Tim Spelman; Shelly Lensing; Rachel Rutishauser; Sonia Bakkour; Michael Busch; Janet D Siliciano; Robert F Siliciano; Mark H Einstein; Dirk P Dittmer; Elizabeth Chiao; Steven G Deeks; Christine Durand; Sharon R Lewin
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.